Literature DB >> 35380267

Genetic susceptibility analysis of FGF5 polymorphism to preeclampsia in Chinese Han population.

Qian Xin1, Ying Han2, Wen Jiang1, Jue Wang1, Yun Luan1, Qinghong Ji3, Wenjuan Sun4.   

Abstract

Fibroblast growth factor 5 (FGF5), which is a well-established causative factor for blood pressure, has been identified as a susceptibility gene for preeclampsia (PE) in European and Central Asian women. Here, we examined whether polymorphism rs16998073 in FGF5 confer a significant risk to PE in Chinese Han population by case-control association analysis. FGF5 rs16998073 was genotyped by Sanger sequencing in women with preeclampsia (n = 187) and healthy controls (n = 229) of Han Chinese. We found the frequency of rs16998073T allele was significantly higher in PE patients than that in controls. Next, we utilized dual-luciferase reporter assays and electrophoretic mobility shift assay (EMSA) reactions to investigate whether rs16998073 different alleles could affect the transcriptional activity of FGF5. The dual luciferase reporter assay showed that T allele increased the transcriptional efficiency by 1.5-fold compared with the G allele. Similarly, EMSA revealed that the T allele had a strong transcription factor binding strength compared with the G allele. We then examined the mRNA and protein expression levels of FGF5 in placental tissues by real-time PCR and Western blot assays. We found FGF5 were significantly upregulated in placental tissues from PE patients or PE mouse model than their corresponding controls. In addition, in vitro cell experiments confirmed that FGF5 could promote cell apoptosis of HTR8/SVneo and inhibit cell invasion. Taken together, our data provide evidence implicating rs16998073 of FGF5 as a functional genetic risk variant for PE disease and FGF5 might participate in development of PE disease.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Association study; FGF5; Preeclampsia; SNP

Mesh:

Substances:

Year:  2022        PMID: 35380267     DOI: 10.1007/s00438-022-01889-z

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   3.291


  26 in total

Review 1.  Preeclampsia; short and long-term consequences for mother and neonate.

Authors:  Anouk Bokslag; Mirjam van Weissenbruch; Ben Willem Mol; Christianne J M de Groot
Journal:  Early Hum Dev       Date:  2016-09-20       Impact factor: 2.079

2.  A historical overview of preeclampsia-eclampsia.

Authors:  Mandy J Bell
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2010 Sep-Oct

3.  FGF5 is a crucial regulator of hair length in humans.

Authors:  Claire A Higgins; Lynn Petukhova; Sivan Harel; Yuan Y Ho; Esther Drill; Lawrence Shapiro; Muhammad Wajid; Angela M Christiano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-02       Impact factor: 11.205

Review 4.  [Preeclampsia - a disease of pregnant women].

Authors:  Anna Filipek; Ewelina Jurewicz
Journal:  Postepy Biochem       Date:  2018-12-29

5.  VEGF-A and VEGFR1 SNPs associate with preeclampsia in a Philippine population.

Authors:  Melissa D Amosco; Van Anthony M Villar; Justin Michael A Naniong; Lara Marie G David-Bustamante; Pedro A Jose; Cynthia P Palmes-Saloma
Journal:  Clin Exp Hypertens       Date:  2016-09-26       Impact factor: 1.749

6.  Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential.

Authors:  N Altorki; G K Schwartz; M Blundell; B M Davis; D P Kelsen; A P Albino
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

7.  FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations.

Authors:  J M Hébert; T Rosenquist; J Götz; G R Martin
Journal:  Cell       Date:  1994-09-23       Impact factor: 41.582

8.  A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for Evaluation of the Efficacy and Safety of DKB114 on Reduction of Uric Acid in Serum.

Authors:  Yu Hwa Park; Do Hoon Kim; Jung Suk Lee; Hyun Il Jeong; Kye Wan Lee; Tong Ho Kang
Journal:  Nutrients       Date:  2020-12-10       Impact factor: 5.717

9.  FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.

Authors:  Sara Ghassemi; Katharina Vejdovszky; Emine Sahin; Lukas Ratzinger; Karin Schelch; Thomas Mohr; Barbara Peter-Vörösmarty; Jelena Brankovic; Andreas Lackner; Alexandra Leopoldi; Diana Meindl; Christine Pirker; Balazs Hegedus; Brigitte Marian; Klaus Holzmann; Bettina Grasl-Kraupp; Petra Heffeter; Walter Berger; Michael Grusch
Journal:  Oncotarget       Date:  2017-09-23

10.  FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy.

Authors:  Jun Iwabu; Satoshi Yamashita; Hideyuki Takeshima; Takayoshi Kishino; Takamasa Takahashi; Ichiro Oda; Kazuo Koyanagi; Hiroyasu Igaki; Yuji Tachimori; Hiroyuki Daiko; Hidetsugu Nakazato; Kazuhiro Nishiyama; Yi-Chia Lee; Kazuhiro Hanazaki; Toshikazu Ushijima
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.